Switch to Richard Klasa's research page...

2007

1. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 18(1):116-21. Epub 2006 Sep 13. (2007).
    [View Abstract - PubMed 16971665]  Request Paper

2. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109(5):1857-61. Epub 2006 Nov 14. (2007).
    [View Abstract - PubMed 17105812]  Request Paper

2006

3. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 17(1):123-30. Epub 2005 Oct 19. (2006).
    [View Abstract - PubMed 16236753]  Request Paper

4. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).
    [View Abstract - PubMed 16183118]  Request Paper

5. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).
    [View Abstract - PubMed 17017873]  Request Paper

6. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 108(10):3295-301. Epub 2006 Jul 27. (2006).
    [View Abstract - PubMed 16873669]  Request Paper

2005

7. Au WY, Gascoyne RD, Klasa RD, Connors JM, Gallagher RP, Le ND, Loong F, Law CK, Liang R. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol. 128(6):792-6. (2005).
    [View Abstract - PubMed 15755282]  Request Paper

8. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 106(6):2169-74. Epub 2005 Jun 2. (2005).
    [View Abstract - PubMed 15933054]  Request Paper

9. Knezevich S, Ludkovski O, Salski C, Lestou V, Chhanabhai M, Lam W, Klasa R, Connors JM, Dyer MJ, Gascoyne RD, Horsman DE. Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia. 19(4):659-63. (2005).
    [View Abstract - PubMed 15716988]  Request Paper

10. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 23(22):5027-33. Epub 2005 Jun 13. (2005).
     [View Abstract - PubMed 15955905]  Request Paper

11. Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Morris J, O'Reilly SE, Pickles T, Sehn L, Connors JM. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer. 103(5):1008-17. (2005).
     [View Abstract - PubMed 15651059]  Request Paper

2004

12. Au WY, Gascoyne RD, Gallagher RE, Le N, Klasa RD, Liang RH, Choy C, Foo W, Connors JM. Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey. Ann Oncol. 15(4):626-30. (2004).
     [View Abstract - PubMed 15033671]  Request Paper

13. Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma. 45(3):519-28. (2004).
     [View Abstract - PubMed 15160914]  Request Paper

14. Henderson LJ, Okamoto I, Lestou VS, Ludkovski O, Robichaud M, Chhanabhai M, Gascoyne RD, Klasa RJ, Connors JM, Marra MA, Horsman DE, Lam WL. Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21. Genes Chromosomes Cancer. 40(1):60-5. (2004).
     [View Abstract - PubMed 15034870]  Request Paper

15. Klasa RJ. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (Williston Park). 18(13 Suppl 10):25-31. (2004).
     [View Abstract - PubMed 15651174]  Request Paper

2003

16. Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM. Limited-stage mantle-cell lymphoma. Ann Oncol. 14(10):1555-61. (2003).
     [View Abstract - PubMed 14504058]  Request Paper

17. Lestou VS, Gascoyne RD, Sehn L, Ludkovski O, Chhanabhai M, Klasa RJ, Husson H, Freedman AS, Connors JM, Horsman DE. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol. 122(5):745-59. (2003).
     [View Abstract - PubMed 12930384]  Request Paper

18. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thieblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 21(1):20-7. (2003).
     [View Abstract - PubMed 12506165]  Request Paper

2002

19. Au WY, Gascoyne RD, Viswanatha DS, Connors JM, Klasa RJ, Horsman DE. Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. Leuk Lymphoma. 43(4):783-91. (2002).
     [View Abstract - PubMed 12153165]  Request Paper

20. Au WY, Horsman DE, Connors JM, Klasa RJ, Gascoyne RD. Cytogenetic findings in reactive lymphoid hyperplasia: significance of non-clonal t(3;14) and t(3;22). Am J Hematol. 70(2):133-8. (2002).
     [View Abstract - PubMed 12111786]  Request Paper

21. Au WY, Horsman DE, Ohno H, Klasa RJ, Gascoyne RD. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma. 43(4):813-6. (2002).
     [View Abstract - PubMed 12153169]  Request Paper

22. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12(3):193-213. (2002).
     [View Abstract - PubMed 12162702]  Request Paper

23. Klasa RJ, Meyer RM, Shustik C, Sawka CA, Smith A, Guevin R, Maksymiuk A, Rubinger M, Samosh M, Laplante S, Grenier JF. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 20(24):4649-54. (2002).
     [View Abstract - PubMed 12488409]  Request Paper

24. Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O'Reilly SE, Sutcliffe S, Connors JM. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 20(1):197-204. (2002).
     [View Abstract - PubMed 11773170]  Request Paper

25. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm. 241(1):57-64. (2002).
     [View Abstract - PubMed 12086721]  Request Paper

2001

26. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res. 7(12):3920-7. (2001).
     [View Abstract - PubMed 11751483]  Request Paper

27. Klasa RJ, List AF, Cheson BD. Rational approaches to design of therapeutics targeting molecular markers. Hematology Am Soc Hematol Educ Program. :443-62. (2001).
     [View Abstract - PubMed 11722998]  Request Paper

2000

28. Au WY, Horsman DE, Viswanatha DS, Connors JM, Klasa RJ, Gascoyne RD. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica. 85(11):1225-7. (2000).
     [View Abstract - PubMed 11064480]  Request Paper

29. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res. 6(6):2492-500. (2000).
     [View Abstract - PubMed 10873104]  Request Paper

1999

30. Au WY, Gascoyne RD, Le N, Viswanatha DS, Klasa RJ, Gallagher R, Connors JM. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 10(3):317-21. (1999).
     [View Abstract - PubMed 10355576]  Request Paper

31. Au WY, Gascoyne RD, Viswanatha DS, Skinnider BF, Connors JM, Klasa RJ, Horsman DE. Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas. Br J Haematol. 105(2):437-40. (1999).
     [View Abstract - PubMed 10233417]  Request Paper

32. Goss P, Stewart AK, Couture F, Klasa R, Gluck S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 34(3-4):295-304. (1999).
     [View Abstract - PubMed 10439366]  Request Paper

33. Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M, Gascoyne RD. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 17(5):1558-67. (1999).
     [View Abstract - PubMed 10334544]  Request Paper

1998

34. Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood. 92(4):1160-4. (1998).
     [View Abstract - PubMed 9694703]  Request Paper

35. Chhanabhai M, Britten C, Klasa R, Gascoyne RD. t(2;5) positive lymphoma with peripheral blood involvement. Leuk Lymphoma. 28(3-4):415-22. (1998).
     [View Abstract - PubMed 9517514]  Request Paper

36. Connors JM, Klasa R. Treatment of follicular lymphoma. Curr Opin Oncol. 10(5):392-5. (1998).
     [View Abstract - PubMed 9800107]  Request Paper

37. James GK, Horsman D, Connors JM, Klasa R, Wilson K, Argatoff L, Gascoyne RD. Clinicopathological analysis of follicular lymphoma with a polyploid karyotype. Leuk Lymphoma. 28(3-4):383-9. (1998).
     [View Abstract - PubMed 9517510]  Request Paper

1997

38. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 89(6):2067-78. (1997).
     [View Abstract - PubMed 9058729]  Request Paper

39. Hoskins PJ, Le N, Gascoyne RD, Klasa R, Shenkier T, O'Reilly S, Connors JM. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. Ann Oncol. 8(11):1125-32. (1997).
     [View Abstract - PubMed 9426332]  Request Paper

40. O'Reilly SE, Connors JM, Macpherson N, Klasa R, Hoskins P. Malignant lymphomas in the elderly. Clin Geriatr Med. 13(2):251-63. (1997).
     [View Abstract - PubMed 9115450]  Request Paper

1996

41. Silver HKB, Klasa RJ, Bally MB. Genetic allogenization of malignant melanoma. Transfus Sci. 17(1):169-74. (1996).
     Request Paper

1995

42. Belch AR, Eisenhauer EA, Muldal A, Browman G, Klasa R, Osterwalder B. Phase II study of subcutaneous rHu-interleukin-2 and rHu-interferon alpha-2a in previously treated patients with multiple myeloma. Ann Oncol. 6(7):721-3. (1995).
     [View Abstract - PubMed 8664195]  Request Paper

43. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, et al.. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood. 86(2):451-6. (1995).
     [View Abstract - PubMed 7541661]  Request Paper

1994

44. Silver HKB, Klasa RJ. Clinical strategies and expectations for the molecular biotherapy of cancer. World Scientific Publishing Co. 5-19. (1994).
     Request Paper

1993

45. O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol. 11(11):2250-7. (1993).
     [View Abstract - PubMed 8229141]  Request Paper

1992

46. Horsman D, Gascoyne R, Klasa R, Coupland R. t(11;18)(q21;q21.1): a recurring translocation in lymphomas of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer. 4(2):183-7. (1992).
     [View Abstract - PubMed 1373320]  Request Paper

1991

47. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 9(3):499-508. (1991).
     [View Abstract - PubMed 1847968]  Request Paper

1990

48. Klasa RJ, Connors JM, Klimo P, O'Reilly S. Treatment of diffuse large cell lymphomas. Progress in Lymphology - XII Amsterdam: Excerpta Medica. 193-7. (1990).
     Request Paper

49. Klasa RJ, Silver HK, Kong S. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Cancer Res. 50(16):4906-10. (1990).
     [View Abstract - PubMed 2379154]  Request Paper

50. Silver HK, Klasa RJ. The biological basis for interleukin-2 anticancer therapy. Prog Clin Biol Res. 354B:37-52. (1990).
     [View Abstract - PubMed 2236173]  Request Paper

51. Silver HKB, Klasa RJ. Therapeutic Opportunities for Interleukin 2. Parthenon Inc. 77-92. (1990).
     Request Paper

1989

52. Klasa R, Silver HKB. Interferons, interleukins and the new biology in cancer therapy. Medicine (North America). 29:5393-8. (1989).
     Request Paper

1988

53. Klasa RJ, Abboud RT, Ballon HS, Grossman L. Goodpasture's syndrome: recurrence after a five-year remission. Case report and review of the literature. Am J Med. 84(4):751-5. (1988).
     [View Abstract - PubMed 3041810]  Request Paper

1997

1. Gascoyne RD, Argatoff LH, Connor JM, Klasa RJ, Horsman DE.. Blood 89:2067-2078 (1997).
    Request Paper

1996

2. Silver HKB, Klasa RJ, Bally MB.. Transfusion Science 17:169-174 (1996).
    Request Paper

1995

3. Belch AR, Eisenhauer EA, Mudal A, Browman G, Klasa RJ, Osterwalder B.. Annals of Oncology 6:721-723 (1995).
    Request Paper

1992

4. Horsman D, Gascoyne R, Klasa RJ, Copeland R.. Genes, Chromosomes and Cancer 4:183-187 (1992).
    Request Paper

1991

5. Klasa RJ, Murray N, Coldman A.. Journal of Clinical Oncology 9:499-508 (1991).
    Request Paper

1990

6. Klasa RJ, Silver HKB, Kong S.. Cancer Research 50:4906-4910 (1990).
    Request Paper